News & Events

Acute myeloid leukemia (AML) is a molecularly heterogeneous disorder characterized by symptoms related to pancytopenia and by an accumulation of immature myeloid precursors that is a consequence of a blockage in normal cellular differentiation. Although the therapeutic approach to AML has remained…

Lung cancer is made up of a group of molecularly and histologically heterogeneous subtypes. Two major histologic subtypes are non–small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), which account for 76% and 13%, respectively, of all cases of lung cancer in the United States. Although…

Acute myeloid leukemia (AML) is primarily a disease of older adults, with a median age of 68 years at diagnosis. Standard curative treatment for AML consists of intensive induction chemotherapy followed by consolidation chemotherapy, allogeneic stem-cell transplantation, or both. However, because…

Chromatin is one of the earliest identified targets for cancer therapeutics. Drug development aimed at altering chromatin can be traced to the differentiating agents of the 1970s and their link to DNA methylation. A more precise understanding of the complexity of chromatin and its role in…

In a recent report, Lee et al. showed a new therapeutic approach: the use of hyaluronic acid–bilirubin nanoparticles to treat acute colitis in a mouse model of inflammatory bowel disease. They used hyaluronate, a potent activator of innate immunity and inducer of type 1 helper T-cell responses, as…

Figure 1.

Figure 1.

The American Cancer Society (ACS) has updated its screening guidelines for cervical cancer. The new guidelines are for people with a cervix with an average risk of cervical cancer.

Figure 1.

Chronic lymphocytic leukemia (CLL) cells proliferate in secondary lymphoid organs (lymph nodes and spleen), where B-cell receptor signaling promotes the expansion of the monoclonal B lymphocytes. B-cell receptor signaling is the target of kinase inhibitors, which have transformed CLL therapy during…